Streetbeat News

Products Services

J

Jacobs has been chosen by the New York Metropolitan Transportation Authority as the program management consultant for the Long Island Rail Road Station Improvements Project. This selection highlights Jacobs' role in a significant infrastructure project.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:46 am

FSUMF

Fortescue Metals (OTC:FSUMF) has announced a $2.8 billion investment in electrifying its fleet, including 475 emission-free machines. Despite challenges like falling iron ore prices, the company is committed to achieving net-zero emissions by 2030, surpassing its peers. The initiative includes partnerships for battery-electric trains and aims to eliminate 95 million liters of diesel annually.

Portfolio Pulse from Stjepan Kalinic

September 25, 2024 | 11:41 am

ACST

Acasti Pharma has completed patient enrollment for its Phase 3 STRIVE-ON safety trial, which is a significant milestone in the development of its product pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:34 am

IFRX

InflaRx announced the presentation of a post hoc analysis of its Phase 2b study on Vilobelimab, an anti-c5a antibody, at the 2024 European Academy of Dermatology and Venereology Congress. This study focuses on its application in treating Hidradenitis Suppurativa.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:33 am

ME

23andMe Holding Co has released a new report for its 23andMe+ premium members, focusing on the genetics of emotional eating. The report informs members if they have a higher likelihood of frequent emotional eating.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:32 am

BCO

The Brink's Company has announced a long-term agreement with Sainsbury's to provide ATM managed services. This partnership is expected to enhance Brink's service offerings and expand its market presence.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:31 am

ORKA

Oruka Therapeutics presented new preclinical data on ORKA-001, a novel monoclonal antibody with an extended half-life, at the European Academy of Dermatology and Venereology Congress. ORKA-001 shows potential for extended dosing intervals in humans, possibly allowing for dosing once every six months or even yearly. It demonstrates similar efficacy to risankizumab but with potentially higher antibody exposures.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:10 am

EBS

Emergent BioSolutions has secured approximately $400 million in orders for 2024 and 2025 related to its Vaccinia, Smallpox, and Mpox product portfolio. This development indicates strong demand for its products and could positively impact the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:08 am

ABBV

AbbVie announced results from a new post-hoc analysis of the Measure Up 1 and Measure Up 2 Phase 3 studies of Upadacitinib in patients with moderate-to-severe atopic dermatitis. The analysis provides insights into the efficacy of Upadacitinib at 15 mg and 30 mg doses.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:06 am

IRDM

Iridium Communications Inc. (NASDAQ:IRDM) is advancing its satellite service with the acceptance of its NB-IoT for Non-Terrestrial Networks into the 3GPP Release 19 Work Plan. This development will enable Iridium's NTN Direct service to offer global 5G NB-IoT connectivity by 2025, leveraging its LEO satellite network.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:05 am